Recent evidence has shown that immediate treatment with rituximab induction, with and without maintenance, substantially reduces the need for further treatment in patients with advanced asymptomatic follicular lymphoma. This analysis estimates the cost-effectiveness of immediate treatment approaches in comparison to a watch and wait approach from the perspective of the UK National Health Service. A Markov decision model was developed to estimate the cost-effectiveness of treatment strategies in patients with asymptomatic follicular lymphoma. The model was populated using effectiveness data from a systematic literature review with the key clinical data sourced from a randomised trial, in which the treatment strategies were compared. Costs were estimated using UK national sources. In comparison to watchful waiting, both rituximab strategies were found to be more effective and cost saving. In comparison to rituximab induction, the addition of rituximab maintenance marginally increased effectiveness but substantially increased costs, resulting in an incremental cost-effectiveness ratio (ICER) of £69 406 per quality-adjusted life year (QALY). In probabilistic sensitivity analysis, rituximab induction was found to have a 68% probability of being cost-effective at a threshold of £20 000 per QALY. In conclusion, active treatment with rituximab induction is a cost-effective strategy to adopt in patients with asymptomatic follicular lymphoma.
As follicular lymphoma has a long natural history, the conventional view is that, apart from very localised stage I disease, which may be ablated by local radiotherapy, there is no advantage in terms of survival for immediate treatment compared to a watch and wait approach. This delays treatment until either the patient develops significant symptoms or there is risk of, or actual dysfunction of a major organ system.
The evidence supporting this approach dates from the pre-rituximab era and there have been significant changes in the management of follicular lymphoma since then. In particular: immunochemotherapy achieves a higher number of responses and prolonged relapse-free survival compared to chemotherapy alone (Hiddemann et al, 2015) ; more intensive chemotherapy (CHOP; cyclophosphamide, doxorubicin, vincristine, prednisone) improves progression-free survival compared to previous approaches using oral chlorambucil or CVP (cyclophosphamide, vincristine, prednisone) (Federico et al, 2013) ; bendamustine has high activity in follicular lymphoma, which may now rival CHOP as the chemotherapy agent of choice (Rummel et al, 2013) ; maintenance treatment continuing for 2 years beyond completion of immunochemotherapy further prolongs relapse-free survival (Salles et al, 2013) ; a recent trial of watch and wait compared to immediate immunotherapy with rituximab has found that twice as many patients in the watch and wait group required treatment after 3 years compared to those who received a short course of rituximab (Ardeshna et al, 2014) .
The availability of more effective treatment and the ability to identify those cases harbouring more aggressive lymphoma have led to uncertainty with regard to the role of a watch and wait approach. However it remains the case that 15-20% of patients may never need intervention over a period of 10-15 years and for whom early chemotherapy would be unnecessary (Ardeshna et al, 2003) . This analysis has therefore been undertaken to estimate the cost-effectiveness of watchful waiting, rituximab induction or rituximab induction followed by maintenance for people with advanced asymptomatic follicular lymphoma.
Methods
A de novo economic evaluation was undertaken to assess cost-effectiveness. A Markov decision model was developed using Microsoft Excel (Fig 1) .
Patients with asymptomatic follicular lymphoma enter the model at the decision point between active treatment with rituximab or watchful waiting. Patients on watchful waiting may eventually require treatment as a result of disease progression or patient preference. Likewise, patients initially treated with one of the rituximab treatment approaches may relapse or have disease progression, at which point further treatment would be required.
For the purposes of the economic analysis, further treatment at this point was termed 'second line treatment' as either active treatment or watchful waiting were deemed to be 'first line treatment'. Patients were assumed to receive one of three immunochemotherapy regimens as second line treatment: rituximab + CHOP (R-CHOP), rituximab + CVP (R-CVP) or rituximab + bendamustine (R-Bendamustine) in equivalent proportions of 33% each. If induction immunochemotherapy was found to be successful, then patients would receive rituximab maintenance.
If patients experience another relapse after second-line treatment, then they will receive a third treatment line, which could be another chemotherapy regimen with or without rituximab or an autologous transplantation. It was assumed that the latter option would only be given to patients <65 years old and that rituximab would not be used in patients with previous non-response or progression within 12 months. If patients responded to rituximab-containing treatment, then they would receive rituximab maintenance. When experiencing a further relapse after third-line treatment or beyond, then it was assumed that another immunochemotherapy regimen would be received. This is reflected in the model as a 'basket' of eleven immunochemotherapy regimens with rituximab maintenance.
Patients could also die from follicular lymphoma or other cause mortality at any point.
The key clinical data for the economic model was from a randomised trial, which compared the three treatment options in the model; watchful waiting, rituximab induction and rituximab induction followed by maintenance (Ardeshna et al, 2014) . In the watchful waiting arm, 54% of patients required new treatment after 3 years. Rituximab induction was shown to reduce the number of patients requiring new treatment with a hazard ratio (HR) of 0Á35 (0Á22-0Á56) in comparison to watchful waiting, equating to 11% needing new treatment after 3 years. Induction with rituximab followed by maintenance further reduced the number of patients requiring new treatment, with a HR of 0Á21 (0Á14-0Á31) in comparison to watchful waiting, equating to 19% needing new treatment after 3 years. In the model, these values were converted to annual recurrence rates of 22Á8%, 6Á7% and 3Á9% for the watchful waiting, rituximab induction and rituximab maintenance arms respectively.
Progression rates after primary management were estimated from the results of the PRIMA trial (Salles et al, 2013) , in which 135 non-mortality related events over the six-year period of follow-up occurred in the 505 follicular lymphoma patients treated with rituximab induction followed by rituximab maintenance. This was converted to an annual recurrence estimate of 5Á1%.
The randomised trial of the three treatment options reported no statistically significant difference in survival between the watchful waiting and the rituximab arms. Therefore it has been assumed that there is no difference in survival between the strategies. Disease-related mortality was captured in the model using combined data from the watchful waiting and rituximab arms of the trial. The combined non-Hodgkin lymphoma-related mortality rate over three years was 3Á7%; this was converted to an annual estimate of 1Á2% in the model (assuming a constant rate of mortality over the study period).
Death from other causes was captured using 2011-2013 life tables for England and Wales from the Office for National Statistics (ONS, 2014) . These life tables give an estimate of the annual probability of death given a person's age and gender. A starting age of 60 years and a male proportion of 46% were applied in the model based on averages in the published study.
A full list of the cost and quality of life (QoL) inputs applied in the model are detailed in Table I . Further detail on each of the key aspects is provided in the relevant sections below.
Rituximab induction with and without maintenance
The drug costs of rituximab induction and maintenance were estimated using dosages and unit costs from the British National Formulary (BNF) (Joint Formulary Committee, 2015) . The cost associated with delivering rituximab was estimated using National Health Service (NHS) reference costs codes associated with the delivery of chemotherapy at first attendance on an outpatient or day case basis. A weighted average of outpatient and day case costs was estimated using the number of procedures.
It was assumed that the frequency and duration of monitoring as well as the investigations used would be the same in the watchful waiting and rituximab arms. While there is likely to be some variation in clinical practice, the follow-up frequency reported in the British Committee for Standards in Haematology Guidelines (McNamara et al, 2012) was used in the economic model.
It was assumed that, at each follow-up visit, the patient would undergo a physical examination and enquiry about symptoms as well as various tests: full blood count, liver and renal function, and immunoglobulin profile. The cost of the consultation was sourced from NHS Reference costs (Department of Health 2014) while the test costs were sourced from a rituximab technology assessment report by the School of Health and Related Research (ScHARR; Papaioannou et al, 2012) and inflated to 2015 prices. It was also assumed that patients would receive a computed tomography (CT) scan if relapse or progression was suspected and to evaluate the response to treatment at appropriate intervals. The cost of a CT scan was sourced from NHS Reference costs (Department of Health 2014) .
Most patients experiencing a recurrence will be treated with immunochemotherapy. The costs associated with delivering chemotherapy were sourced from NHS Reference costs (Department of Health 2014) , with different costs used depending on whether the regimen is delivered on an outpatient, day case or inpatient basis. The unit costs of drugs were sourced from the electronic market information tool (eMIT; Department of Health, Commercial Medicines Unit, 2011). Where eMIT costs were not available, BNF costs were used (Joint Formulary Committee, 2015) .
In the case of carmustine, unit costs were not available from eMIT or the BNF due to a recent lack of availability of the drug, which is now only available through specialist importers. In this case, the cost was estimated to be £358Á80 per 100 mg based upon the most recent price paid at The Christie NHS Foundation Trust pharmacy (Personal communication, Kim Linton, The Christie NHS Foundation Trust, Manchester).
For patients receiving immunochemotherapy in second and third treatment lines, it was assumed that R-CHOP, RBendamustine or R-CVP would be received. It was assumed that all three regimens were equally likely to be received. However, since the costs of the regimens are very similar, the proportion of patients receiving each one is unlikely to affect the results. For patients receiving immunochemotherapy in fourth or subsequent treatment lines, it was assumed that patients would receive one of 11 immunochemotherapy (2014) regimens that might be used in this setting; R-CHOP, R-CVP, R-Bendamustine, R-ESHAP (rituximab, etoposide, methylprednisolone, cytarabine, cisplatin), R-DHAP (rituximab, dexamethasone, high-dose cytarabine, cisplatin), R-GDP (rituximab gemcitabine, dexamethasone, cisplatin), R-ICE (rituximab, ifosfamide, carboplatin, etoposide), R-GEMP (rituximab, gemcitabine, cisplatin, methylprednisolone, R-FC (rituximab, fludarabine, cyclophosphamide), R-GCVP (rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) or R-Mini-BEAM (rituximab + reduced doses of carmustine, etoposide, cytarabine, melphalan). The average cost associated with this basket of regimens was estimated (assuming an equivalent proportion of each regimen was used) and applied for each subsequent relapse. It was assumed that granulocyte-colony stimulating factor (GCSF) would be used in 50% of patients receiving chemotherapy. The unit costs associated with GCSF agents (lenograstim or filgrastim, including biosimilars) were sourced from the BNF as unit costs were not available from eMIT. It was assumed that GCSFs would be administered for seven days.
The guideline committee estimated the cost of an autologous transplantation procedure to be £34 000 based upon locally-used tariffs. It was assumed that patients undergoing an autologous transplant would first receive three cycles of salvage chemotherapy. Numerous chemotherapy regimens are used for this purpose but it was thought that these would be the most commonly used. Therefore the average cost of four commonly used regimens, R-ESHAP, R-DHAP, R-GDP and R-ICE, was applied in the economic analysis.
The cost of palliative care was sourced from a costing report by the Nuffield Trust (Georghiou & Bardsley, 2014) . A cost of £7287 was applied based on the average resource use of patients with cancer in the last 3 months of life.
The model estimates effectiveness in terms of QALYs, so that both the quantity and quality of life are taken into account. QALYs were estimated by combining the life year estimates with utility values or QoL weights associated with being in a particular health state.
The QoL data were sourced from an unpublished Oxford Outcomes study that was utilised in the National Institute for Health and Care Excellence (NICE) technology appraisal for rituximab in the first-line treatment of stage III-IV follicular lymphoma. Further details of the study were subsequently published in the accompanying technology assessment report by ScHARR (Papaioannou et al, 2012) .
It was assumed that the QoL value associated with asymptomatic follicular lymphoma would be equivalent to 'disease free' patients (utility value of 0Á880 based on 27 patients). Using the approach adopted in the ScHARR technology assessment report, the QoL values associated with symptomatic follicular lymphoma and progressive disease were estimated to be 0Á8050 and 0Á7363, respectively, based upon aggregated utility values for 'progression free' (n = 84) and 'disease progression' (n = 132) health states.
A further assumption was that first-line treatment with rituximab does not have an associated QoL decrement. This assumption was based on the results from the randomised trial (Ardeshna et al, 2014) , which showed that overall there was no QoL detriment associated with rituximab in comparison to watchful waiting. In addition QoL decrements associated with treatment-related morbidity were not incorporated in the base case analysis because there was no high quality data available in this area and also because of concerns that the QoL impact associated with treatment-related morbidity may already be captured in the QoL data.
The model was run over a 40-year time horizon with total costs and QALYs estimated for each treatment strategy, and future costs and benefits discounted at a rate of 3Á5% per year as recommended by NICE (2014).
Results
The base case results of the analysis for are presented in Table II . In comparison to watchful waiting, both rituximab induction and rituximab induction followed by rituximab maintenance were found to be cost-effective and, indeed, dominant (i.e. more effective and cost saving). Rituximab induction was found to be the optimal strategy overall. The addition of rituximab maintenance was found to be marginally more effective but it also substantially increased cost, so that it was not cost-effective with an incremental cost-effectiveness ratio (ICER) of £69 406, well above the NICE threshold of £20 000 per QALY (NICE 2014) .
A series of deterministic sensitivity analyses were conducted, whereby an input parameter is changed, the model is re-run and the new cost-effectiveness result is recorded. This estimates uncertainty and determines the key drivers of the model result. The results of the one-way sensitivity analysis are shown in Table III .
It can be seen that rituximab induction remains the optimal strategy in most analyses. The notable exceptions were the upper HR for starting new treatment after rituximab induction, making it less effective and the lower HR for starting new treatment after rituximab induction followed by maintenance, making it more effective. In these scenarios, it was found that rituximab induction followed by rituximab maintenance became the optimal strategy because its relative effectiveness in comparison to rituximab induction was improved.
One of the distinguishing features of this analysis in comparison to previous economic evaluations of watchful waiting and active treatment in other disease areas, was that there was assumed to be no QoL benefit for patients on watchful waiting in comparison to active treatment. This is consistent with the data from the randomised study which showed that QoL with rituximab was at least as good as, and probably better than, watchful waiting (Prica et al, 2015) .
Therefore, a threshold analysis was conducted to ascertain the QoL improvement required in patients on watchful waiting, over and above active treatment with a rituximab strategy, for watchful waiting to become cost-effective at a threshold of £20 000 per QALY. It was found that watchful waiting becomes cost-effective when it was assumed that QoL is 0Á105 lower for patients receiving rituximab in comparison to watchful waiting strategies.
Probabilistic sensitivity analysis was also conducted to assess the combined parameter uncertainty in the model. In this analysis, the mean values that are utilised in the base case are replaced with values drawn from distributions around the mean values.
The results of 10 000 runs of the probabilistic sensitivity analysis are shown using the cost-effectiveness acceptability curve (CEAC) in Fig 2 ( results are also depicted with ICER scatter plots [ Figures S1, S2 ] in the supplementary material). The CEAC shows the probability of each strategy being considered cost-effective at the various cost-effectiveness thresholds on the x-axis. At a willingness to pay threshold of £20 000 per QALY, rituximab induction has a 68% probability of being cost-effective, while rituximab induction followed by rituximab maintenance has a 21% probability of being cost-effective and watchful waiting has an 11% probability of being cost-effective.
Discussion
This analysis aimed to estimate the cost-effectiveness of an active treatment strategy with rituximab compared to watchful waiting for patients with newly diagnosed asymptomatic advanced (stage II-IV) follicular lymphoma. This is the first model that has investigated these treatment approaches in the UK context. One previous similar analysis (Prica et al, 2015) was identified but this considered the Canadian health care system and was therefore not directly applicable to the UK context.
The results of the base case analysis suggest that using an active treatment strategy with rituximab induction AE maintenance is cost-effective in comparison to a watchful waiting approach. Indeed, the results suggest that these strategies would be cost saving as well as more effective (i.e. dominant). Rituximab induction alone was found to be the preferred strategy overall as it was much cheaper than the rituximab induction followed by rituximab maintenance strategy with only marginally lower effectiveness.
In the deterministic sensitivity analysis, these findings were found to be robust with the conclusion remaining unchanged Lower hazard ratio (0Á14) for starting new treatment after R-maintenance R-maintenance Upper hazard ratio (0Á31) for starting new treatment after R-maintenance R-induction Lower hazard ratio (0Á22) for starting new treatment after R-induction R-induction Upper hazard ratio (0Á56) for starting new treatment after R-induction R-maintenance Average age = 50 years old R-induction Average age = 70 years old R-induction Subsequent relapse rates = 4Á8% (rate after R-maintenance in first line) R-induction Subsequent relapse rates = 0% R-induction Time horizon = 3 years R-induction BCNU (Carmustine) cost = £1000 per 100 mg R-induction NHS Reference cost used for autologous transplant R-induction Subsequent treatment costs = £0 R-induction Subsequent treatment costs + 50% R-induction Asymptomatic QoL value = progression free QoL value R-induction QoL on WW 0Á01 higher than QoL with rituximab R-Induction QoL on WW 0Á05 higher than QoL with rituximab R-Induction No differences in QoL values R-Induction R-resistance -(relapse rate 50% higher in subsequent lines after R in first line) R-induction R-resistance -(relapse rate 100% higher in subsequent lines after R in first line) R-Induction NHS, National Health Service; QoL, quality of life; R, rituximab.
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in the vast majority of modelled scenarios. Furthermore, in probabilistic sensitivity analysis, rituximab induction was found to have the highest probability of being cost-effective (68%) at the £20 000 per QALY threshold.
There were a few limitations to the analysis. The use of NHS reference costs and drug costs from the BNF, where eMit costs were not available, may not represent local pricing within the NHS, where contracts are based on negotiated discount prices. These were however discussed in the NICE Guideline Committee, which includes clinicians working in a variety of different secondary care settings across the UK. Where their 'sense check' suggested costings were not appropriate, these were re-evaluated.
There is a paucity of QoL data in this area. The key QoL values applied in this model were sourced from an unpublished QoL study that was utilised in the NICE technology appraisal for rituximab (Papaioannou et al, 2012) . As the source study is unpublished, it was difficult to fully appraise its quality. However, while there is uncertainty, it should be noted that the quantity of QALY benefits was not found to be a crucial determinant of the model result in the comparison between the rituximab strategies and the watchful waiting approach. The key QoL aspect of the model relates to the reduction in QoL associated with relapses and progression and it is the direction of this effect that is important rather than the magnitude.
A further limitation is the uncertainty around treatment in subsequent therapy lines. For simplicity and practicality, it has been assumed in the model that patients receive a maximum of five treatment lines but it is not uncommon for patients to receive more lines than this. In treatment lines two and three, it was assumed that patients would receive one of three immunochemotherapy regimens identified as being the treatments which are most likely to be received in clinical practice. There is some evidence that rituximab re-treatment may be an option in patients that initially responded to rituximab induction (Kahl et al, 2014) . However, this is not usual practice at present and so was not captured in the analysis. The treatment received in lines four and five was assumed to be an average of commonly used immunochemotherapy regimens. Some patients may receive alternative immunochemotherapy regimens or another form of treatment, such as further transplant or radiotherapy. However, the modelled pathway is likely to be representative of the most common pathway followed by patients. Furthermore, this aspect of the model was not very influential on the conclusions of the analysis as, even when subsequent treatment costs were set to zero, rituximab was still found to be cost-effective.
The use of Rituximab may reduce immunoglobulin levels, making substitute infusions necessary. The potential need for immunoglobulin infusions in some patients receiving rituximab was not considered in the analysis. The proportion of patients that might require substitute infusions is not known but it was thought that the risk would be low, especially in patients treated with rituximab induction without maintenance. Therefore, it was not thought necessary to include this aspect in the analysis.
Conclusion
The results of the base case analysis suggest that rituximab induction alone is the most cost-effective strategy to adopt in patients with asymptomatic follicular lymphoma. This result was shown to be robust in one-way and probabilistic sensitivity analysis.
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